Matches in Nanopublications for { ?s ?p "[Employing EGFR inhibition with erlotinib specifically at this premalignant stage was effective in decreasing the incidence of ER-negative breast tumors in this mouse model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 12 of
12
with 100 items per page.
- NP900274.RARzhsUFTI9Qu-QTmMnmsvVv7CXmbx8WqBO5y4_PpmEIg130_assertion description "[Employing EGFR inhibition with erlotinib specifically at this premalignant stage was effective in decreasing the incidence of ER-negative breast tumors in this mouse model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP900274.RARzhsUFTI9Qu-QTmMnmsvVv7CXmbx8WqBO5y4_PpmEIg130_provenance.
- assertion description "[Employing EGFR inhibition with erlotinib specifically at this premalignant stage was effective in decreasing the incidence of ER-negative breast tumors in this mouse model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Employing EGFR inhibition with erlotinib specifically at this premalignant stage was effective in decreasing the incidence of ER-negative breast tumors in this mouse model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Employing EGFR inhibition with erlotinib specifically at this premalignant stage was effective in decreasing the incidence of ER-negative breast tumors in this mouse model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Employing EGFR inhibition with erlotinib specifically at this premalignant stage was effective in decreasing the incidence of ER-negative breast tumors in this mouse model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP369002.RAUra8AN4jYtiFVOuo8qw9cXU3M5DcrxB3eCH319LD4JE130_assertion description "[Employing EGFR inhibition with erlotinib specifically at this premalignant stage was effective in decreasing the incidence of ER-negative breast tumors in this mouse model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP369002.RAUra8AN4jYtiFVOuo8qw9cXU3M5DcrxB3eCH319LD4JE130_provenance.
- NP762999.RA235PPyqnfgv3Q0ZeB2-0k_WhNBBzOfEnK6FW5sWdT8w130_assertion description "[Employing EGFR inhibition with erlotinib specifically at this premalignant stage was effective in decreasing the incidence of ER-negative breast tumors in this mouse model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP762999.RA235PPyqnfgv3Q0ZeB2-0k_WhNBBzOfEnK6FW5sWdT8w130_provenance.
- NP878863.RAeNTNgN6zrBrp4jVrxlNjBf1Vo9h1SdOqGot1nl80r-U130_assertion description "[Employing EGFR inhibition with erlotinib specifically at this premalignant stage was effective in decreasing the incidence of ER-negative breast tumors in this mouse model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP878863.RAeNTNgN6zrBrp4jVrxlNjBf1Vo9h1SdOqGot1nl80r-U130_provenance.
- NP384170.RA2j2CQ18NcyPWrLBgmfsuONLjd8t_BZ9Xvy5NEttVhbc130_assertion description "[Employing EGFR inhibition with erlotinib specifically at this premalignant stage was effective in decreasing the incidence of ER-negative breast tumors in this mouse model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP384170.RA2j2CQ18NcyPWrLBgmfsuONLjd8t_BZ9Xvy5NEttVhbc130_provenance.
- NP878862.RA6aJjHvWNj5oMpABz7k-qppvfeu-pscukNITlsN8MBW8130_assertion description "[Employing EGFR inhibition with erlotinib specifically at this premalignant stage was effective in decreasing the incidence of ER-negative breast tumors in this mouse model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP878862.RA6aJjHvWNj5oMpABz7k-qppvfeu-pscukNITlsN8MBW8130_provenance.
- NP878865.RA6tKo3XYSpbwSOFbWO9FzPm4QNof4kUzpAfLwpXU4yJo130_assertion description "[Employing EGFR inhibition with erlotinib specifically at this premalignant stage was effective in decreasing the incidence of ER-negative breast tumors in this mouse model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP878865.RA6tKo3XYSpbwSOFbWO9FzPm4QNof4kUzpAfLwpXU4yJo130_provenance.
- NP878867.RA8s8AouYducWhNWpGMdMrigwRa0NaqFfkJRDpOgYMVWc130_assertion description "[Employing EGFR inhibition with erlotinib specifically at this premalignant stage was effective in decreasing the incidence of ER-negative breast tumors in this mouse model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP878867.RA8s8AouYducWhNWpGMdMrigwRa0NaqFfkJRDpOgYMVWc130_provenance.